💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Enrollment halfway there in Bellerophon's late-stage study of INOpulse in pulmonary arterial hypertension, interim data expected mid-year

Published 01/29/2018, 10:37 AM
© Reuters.  Enrollment halfway there in Bellerophon's late-stage study of INOpulse in pulmonary arterial hypertension, interim data expected mid-year
AGN
-
BLPH
-
  • Bellerophon Therapeutics (BLPH +0.8%) reports that enrollment in its Phase 3 INOvation-1 study evaluating INOpulse in patients with pulmonary arterial hypertension is now over 100, more than halfway to the target.
  • Interim data should be available mid-year with topline results from the full study to follow by year-end.
  • INOpulse is a drug-device combination system that delivers pulsed doses of nitric oxide. It is portable, suitable for at-home use and automatically adjusts to the patient's breathing patterns to deliver consistent dosing.
  • Previously: Bellerophon's INOpulse shows treatment benefit in mid-stage study; shares ahead 15% premarket (Sept. 5, 2017)
  • Now read: Your Daily Pharma Scoop: Ardelyx Reports Data, Omeros Moves Forward With OMS721, Allergan (NYSE:AGN) Announces Job Cuts


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.